Provided by Tiger Trade Technology Pte. Ltd.

Vertex, Inc.

12.01
-0.2900-2.36%
Post-market: 12.010.00000.00%19:30 EDT
Volume:1.40M
Turnover:16.84M
Market Cap:1.95B
PE:544.96
High:12.50
Open:12.42
Low:11.96
Close:12.30
52wk High:26.54
52wk Low:10.21
Shares:162.00M
Float Shares:70.89M
Volume Ratio:0.86
T/O Rate:1.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0220
EPS(LYR):0.0444
ROE:1.46%
ROA:0.65%
PB:8.07
PE(LYR):270.52

Loading ...

Vertex Minerals lodges 2026 corporate governance statement with ASX

TIPRANKS
·
Oct 02

Vertex adds AI-focused independent director to board

TIPRANKS
·
Oct 02

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Oct 02

Vertex appoints Saha to Board of Directors

TIPRANKS
·
Oct 01

Vertex Appoints Datarobot CEO Debanjan Saha to Board of Directors

THOMSON REUTERS
·
Oct 01

Press Release: Vertex Appoints DataRobot CEO Debanjan Saha to Board of Directors

Dow Jones
·
Oct 01

Vertex Pharmaceuticals Price Target Raised to $615.00/Share from $585.00 by UBS

Dow Jones
·
Sep 29

UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating

MT Newswires Live
·
Sep 28

Vertex Minerals Sets October General Meeting for Shareholders

TIPRANKS
·
Sep 25

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 25

Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed

TIPRANKS
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 23

Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Sep 23

TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating

MT Newswires Live
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), AnaptysBio (ANAB) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Sep 23

Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated

TIPRANKS
·
Sep 23

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Dow Jones
·
Sep 23

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

TIPRANKS
·
Sep 22

Maze jumps 25% to $27.99 after Vertex kidney disease data

TIPRANKS
·
Sep 22

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live
·
Sep 22